Sublingual immunotherapy for peanut allergy: a randomized, double-blind, placebo-controlled multicenter trial
DM Fleischer, AW Burks, BP Vickery… - Journal of allergy and …, 2013 - Elsevier
BACKGROUND: There are presently no available therapeutic options for patients with
peanut allergy. OBJECTIVE: We sought to investigate the safety, efficacy, and immunologic
effects of peanut sublingual immunotherapy (SLIT). METHODS: After a baseline oral food
challenge (OFC) of up to 2 g of peanut powder (approximately 50% protein; median
successfully consumed dose [SCD], 46 mg), 40 subjects, aged 12 to 37 years (median, 15
years), were randomized 1: 1 across 5 sites to daily peanut or placebo SLIT. A 5-g OFC was …
peanut allergy. OBJECTIVE: We sought to investigate the safety, efficacy, and immunologic
effects of peanut sublingual immunotherapy (SLIT). METHODS: After a baseline oral food
challenge (OFC) of up to 2 g of peanut powder (approximately 50% protein; median
successfully consumed dose [SCD], 46 mg), 40 subjects, aged 12 to 37 years (median, 15
years), were randomized 1: 1 across 5 sites to daily peanut or placebo SLIT. A 5-g OFC was …